Vaccine development against HIV-1: Current perspectives and future directions

Immunologic Research

Volumn 25, Issue 1, 2002, Pages 53-74

  Edgeworth, Rebecca L ^a   San Juan, Homero ^a   Rosenzweig, Jason A ^a   Nguyen, Nang L ^a   Boyer, Jean D ^a   Ugen, Kenneth E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AIDS; AIDS vaccines; Animal models for HIV 1 vaccines; DNA vaccine; HIV vaccines; HIV 1; Human clinical trials; Protective immunity; Subunit vaccine; Viral vector vaccine

Indexed keywords

ADJUVANT; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; DNA VACCINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; PLASMID DNA; PROTEIN SUBUNIT; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT GLYCOPROTEIN GP 160; SUBUNIT VACCINE; TOXOID; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CAT; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PLASMID; PRIMATE; PRIORITY JOURNAL; RAT; REVIEW; VACCINATION;

AIDS VACCINES; ANIMALS; CATS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MICE; PRIMATES; RETROVIRIDAE INFECTIONS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 0036180579     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:25:1:53     Document Type: Review

References (122)

1. Human trials of experimental AIDS vaccines
2. Delayed progression of murine AIDS in C57BL.6 mice pre-immunized with a highly antigenic 10-mer peptide encoded by the murine AIDS defective virus gag p12 gene
3. Whole-killed gp 120-depleted HIV-1 antigen in a murine model for prophylactic vaccination
4. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site
5. FIV infection of the domestic cat: An animal model for AIDS
6. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines
7. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies
8. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: Protection conferred by a fixed cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted
9. AIDS vaccination studies using feline immunodeficiency virus as a model: Immunization with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus
10. DNA vaccination afford significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
11. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines
12. Enhancement after feline immunodeficiency virus vaccination
13. Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus
14. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection
15. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins
16. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope
17. Attempt to modify the immune response developed against FIV gp 120 protein by preliminary FIV DNA injection
18. Efficacy evaluation of prime-boost protocol: Canary-poxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats
19. Genetic diversity of simian immunodeficiency virus from West African green monkeys: Evidence of multiple genotypes within populations from the same geographical locale
20. Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis
21. Induction of AIDS-like diseases in macaque monkeys with T-cell tropic retroviruses STLV-III
22. The simian immunodeficiency viruses
23. Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge
24. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simianhuman immunodeficiency virus infection
25. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge
26. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus
27. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
28. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
29. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
30. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
31. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells
32. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
33. Identification of highly attenuated mutants of simian immunodeficiency virus
34. Simian immunodeficiency virus DNA vaccine trial in macaques
35. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
36. Outcome of immunization of cynomologous monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
37. Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins
38. Persistent infection with SIV mac chimeric virus having tat, rev, vpa, env and nef of HIV type 1 in macaque monkeys
39. + T cells and AIDS in pig-tailed macaques
40. + T cell loss and AIDS in rhesus macaques
41. Infection of baboons with simian/human immunodeficiency viruses
42. Infection of baboons with a simian immunodeficiency virus/HIV-1 chimeric virus constructed with an HIV-1 Thai subtype E envelope
43. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1
44. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp 160
45. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
46. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees
47. Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: Prelude to a clinical trial
48. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
49. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees
50. Comparison of the immune response to recombinant gp 120 in humans and chimpanzees
51. Recombinant gp 160 as a therapeutic vaccine for HIV-infection: Results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group
52. Repeated immunization with recombinant gp 160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T cell proliferative response
53. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp 120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp 120 or rgp 160 compared with nonimmunized and uninfected controls
54. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
55. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children
56. Immunization with envelope MN rgp 120 vaccine in human immunodeficiency virus-infected pregnant women
57. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen
58. Preliminary evaluation of human immunodeficiency virus type 1 (HIV- 1) immunogen in children with HIV-1 infection
59. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals
60. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen
61. HIV-IMN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-IMN recombinant glycoprotein 120 vaccine
62. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles
63. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp 160 envelope vaccine
64. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp 120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
65. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates
66. Development of peptide vaccines inducing production of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice
67. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials
68. Epitope insertion into variable loops of HIV-1 gp 120 as a potential means to improve immunogenicity of viral envelope protein
69. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice
70. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
71. Control of SHIV-89.6P-infection of cynomologus monkeys by HIV-1 Tat protein vaccine
72. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice
73. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
74. Human rhinovirus type 14: Human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1
75. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp 120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
76. + cytotoxic T lymphocyte responses in seronegative volunteers
77. HIV-1 DNA vaccines
78. Maturation of immune responses to lentivirus infection: Implications for AIDS vaccine development
79. Antibody neutralization of HIV-1 and the potential for vaccine design
80. Beta chemokine levels in non-human primates modulated in vivo by HIV-1 DNA vaccines
81. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
82. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
83. Toward an understanding of the correlates of protective immunity to HIV infection
84. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
85. The search for a potent DNA vaccine against AIDS: The enhancement of immunogenicity by chemical and genetic adjuvants
86. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
87. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
88. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
89. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
90. DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses
91. HIV-1 DNA vaccines and chemokines
92. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1
93. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
94. Engineering DNA vaccines via codelivery of co-stimulatory molecule genes
95. B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination
96. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants
97. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
98. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and IL-12 expressing plasmids
99. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp 160 envelope gene using mammalian codons
100. Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap
101. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors
102. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
103. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat
104. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
105. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
106. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
107. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
108. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
109. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
110. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
111. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
112. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1
113. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1
114. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannancoated liposomes and inhibited by anti-interferon-gamma antibody
115. Cationic microparticles: A potent delivery system for DNA vaccines
116. Macaques immunized with HLADR are protected from challenge with simian immunodeficiency virus
117. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
118. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp 120 SF-2 recombinant vaccines in uninfected volunteers
119. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp 120, HIV-1SF2 recombinant gp 120, or both vaccines in seronegative adults
120. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
121. AVEG031: Phase I evaluation of a gag-pol facilitated DNA vaccine for HIV-1
122. Advacing AIDS VAX to phase 3. Safety, immunogencity, and plans for phase 3